Enel Health®Atlas
Sign in
Enel Health®Atlas
Browse libraries

Not medical advice. The Atlas is not a substitute for a clinician who can examine you.

Liraglutide

Victoza / Saxenda (GLP-1 Analog)

Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.

Liraglutide is an FDA-approved GLP-1 receptor agonist backed by an extensive human RCT record: the six-trial LEAD phase 3 program established glycemic efficacy (HbA1c reductions up to ~1.6%) supporting the 2010 Victoza approval for type 2 diabetes; the SCALE program (Pi-Sunyer et al., NEJM 2015, N=3,731) supported the 2014 Saxenda obesity approval; and the LEADER cardiovascular outcomes trial (Marso et al., NEJM 2016, N=9,340) showed a significant reduction in major adverse cardiovascular events (HR 0.87). grade 5 is warranted for the approved diabetes and obesity indications, though liraglutide is now largely superseded in efficacy by semaglutide and tirzepatide.

FDA
FDA Approved (Victoza, Saxenda)
WADA
Not prohibited

Reference only. Not medical advice.

What can go wrong

Daily injection (vs. weekly semaglutide); GI side effects; less effective than newer agents.

Talk to a clinician before taking this, particularly if you have a thyroid condition. The Atlas can tell you what has been studied about Liraglutide. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.

A once-daily GLP-1 receptor agonist and the direct predecessor to semaglutide, FDA-approved for type 2 diabetes and obesity. Outpaced by newer agents but still widely prescribed and cheaper in some markets.

What people take it for

What it is taken for. Approval, where it exists, covers only some of these.

  • Type 2 diabetes
  • Obesity / weight loss
Type 2 diabetes (Victoza)
FDA-approved in 2010 to improve blood-sugar control in adults, and later in children 10 and older, with type 2 diabetes, and to reduce cardiovascular risk in adults with type 2 diabetes and heart disease.
Chronic weight management (Saxenda)
FDA-approved in 2014 for adults with obesity, and in 2020 for adolescents 12 and older, making it the first GLP-1 approved for pediatric weight management.

How it works

Liraglutide is a GLP-1 receptor agonist that closely imitates the body’s own gut hormone GLP-1. It prompts the pancreas to release insulin when blood sugar is high, suppresses excess glucagon, slows the stomach’s emptying, and increases fullness. The result is better blood-sugar control along with reduced appetite and weight. Because it is engineered to last about a day in the body, it can be taken as a single daily injection, a meaningful convenience advance when it arrived.

Liraglutide is a near-copy of human GLP-1, about 97% identical with a single amino-acid change, plus an added fatty-acid side chain that latches onto a blood protein and stretches its half-life to roughly 13 hours, enabling once-daily dosing. Developed by Novo Nordisk, this human-sequence design was a more elegant solution than the earlier, lizard-derived exenatide, giving smoother dosing and less immune reaction.

Type
GLP-1 receptor agonist
Design
Human GLP-1 analogue
Dosing
Once daily
Approved
Diabetes 2010, obesity 2014
CV benefit
Yes (LEADER)
Status
Now generic

Proven, Affordable, And Outpaced

Liraglutide was a genuine advance whose story is now about progress rather than doubt. It was the first once-daily GLP-1, the first approved for both diabetes (Victoza, 2010) and weight management (Saxenda, 2014), the first GLP-1 with proven cardiovascular benefit, and one of the very few in this field approved for adolescents, all backed by large, rigorous trials. It is thoroughly evidence-anchored and approved, the kind of validated medicine worth holding up as a standard. The honest note concerns efficacy, not legitimacy: on weight loss it has been clearly outpaced, roughly 8% against semaglutide’s 15% and tirzepatide’s 22% in trials, and it lost a head-to-head trial to semaglutide. But with generics now available, including the first generic GLP-1 for weight loss, it has become a proven, affordable daily option that still fits specific patients.

Safety in detail

  • Gastrointestinal effects, nausea, diarrhea, vomiting and reduced appetite, are the most common, typical of the GLP-1 class.
  • It carries the class boxed warning about thyroid C-cell tumors seen in rodents, and a pancreatitis caution.
  • Because it works glucose-dependently, hypoglycemia risk is low on its own.
  • It is a once-daily injection, more frequent than the newer weekly drugs.
  • It is among the best-characterized GLP-1 drugs, with extensive trial and real-world safety data.

Children and teenagers

Liraglutide is one of the few compounds in this library with genuine, evidence-based pediatric approval: for children 10 and older with type 2 diabetes, and for adolescents 12 and older with obesity, the first GLP-1 approved for pediatric weight management. These uses belong strictly within supervised specialist care for real medical conditions, and are entirely different from casual or cosmetic weight-loss use. Within that approved, supervised context, it is a legitimate pediatric medicine; outside it, GLP-1 drugs are not for self-directed use in minors.

What people get wrong

Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.

Who profits, and who pushes back

Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.

Liraglutide was developed and sold by Novo Nordisk as Victoza for diabetes and Saxenda for weight loss, both major products. As its patents expired, generic manufacturers entered, bringing generic liraglutide for diabetes and, notably, the first generic GLP-1 indicated for weight loss. Commercially it has shifted from a premium branded drug to a proven molecule competing on price, even as Novo Nordisk’s newer semaglutide leads the market.

How we got here

Liraglutide was developed by Novo Nordisk under the code name NN2211 and reached market as two brands with the same active ingredient: Victoza, approved for type 2 diabetes (US 2010), and Saxenda, the higher-dose version approved for chronic weight management (2014). It served as the once-daily predecessor to the company's later weekly GLP-1 agonist semaglutide. The molecule became available as a generic in 2024, when Teva launched the first authorized generic GLP-1 agonist and the FDA cleared Hikma's generic version of Victoza.

Novo Nordisk developed liraglutide and brought it to market as Victoza for type 2 diabetes in 2010, followed by the higher-dose Saxenda for obesity in 2014. The 2016 LEADER trial made it the first GLP-1 with proven cardiovascular benefit, and pediatric approvals followed for diabetes in 2019 and adolescent obesity in 2020. As semaglutide and tirzepatide surpassed it on weight loss, liraglutide’s patents expired, and from 2024 onward generics arrived, including the first generic GLP-1 for weight loss, repositioning it as a proven, affordable option.

  1. 2010Approved as Victoza for type 2 diabetes, the first once-daily GLP-1.
  2. 2014Approved as Saxenda for chronic weight management.
  3. 2016The LEADER trial proves cardiovascular benefit.
  4. 2019-2020Pediatric approvals for diabetes and then adolescent obesity.
  5. 2024-2025Generics arrive, including the first generic GLP-1 for weight loss.

The numbers behind the grade

Type
GLP-1 agonist
Design
Human GLP-1 analogue
Dosing
Once daily
Weight loss
~8%
CV benefit
Yes (LEADER)
Status
Now generic

The people taking it

The first once-daily GLP-1 and the first approved for both diabetes and weight loss, a proven, cardiovascular-validated drug now going generic, though outpaced on weight loss by the newer GLP-1s.

Liraglutide’s users are people with type 2 diabetes, especially those with heart disease who benefit from its cardiovascular data, and people with obesity, including adolescents, using it for weight management. It also suits those who prefer a daily, short-half-life option, fit step-therapy requirements, or want a lower-cost generic. It is an approved medicine used under normal medical care.

Approved for type 2 diabetes and weight management, including in adolescents, with proven cardiovascular benefit and now generic availability. Outpaced on weight loss by semaglutide and tirzepatide.

Set against the alternatives

The decisive comparison is to semaglutide: semaglutide doses once weekly, produces roughly double the weight loss, and has cardiovascular-outcome data in non-diabetic people, advantages liraglutide lacks, though liraglutide answers with proven cardiovascular benefit in diabetes, genuine pediatric approvals, and now lower generic pricing. Against tirzepatide, the efficacy gap is even wider, around 22% weight loss versus 8%. And against exenatide, liraglutide was the refined human-sequence, once-daily successor that improved on the pioneer. Its strength is being thoroughly proven and now affordable; its limitation is that newer drugs simply do more for weight loss.

What we do not know

  • What role liraglutide retains now that more effective GLP-1 drugs exist and it has gone generic.
  • Whether its daily dosing and short half-life suit certain patients better than weekly drugs.
  • How widely its genuine pediatric and cardiovascular indications should shape its use.

What could change

Generic eraAffordability is now its main advantage as generics spread.Niche fitIt still suits adolescents, step-therapy, daily-dosing preference and cardiovascular-proven diabetes care.Efficacy contrastIts standing is defined by how much more the newer GLP-1 drugs achieve.

The market for this

What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.

Liraglutide is a prescription medication obtained through standard medical and pharmacy channels, not a gray-market product. Generic liraglutide offers a proven, lower-cost option, while newer GLP-1 drugs provide greater weight loss for those who need and can access them.

Branded Victoza and Saxenda were expensive, but generic liraglutide has lowered the cost considerably, which is much of its current appeal. It is typically cheaper than the newer, more effective GLP-1 drugs.

Liraglutide comes from regulated pharmaceutical manufacturing in both branded and generic forms, with full quality assurance, unlike the gray-market peptides elsewhere in this library.

Regulated pharmaceuticalLiraglutide is an approved, regulated prescription drug in both branded and generic forms, not a gray-market peptide.Branded originNovo Nordisk’s Victoza and Saxenda established it clinically and commercially.Generic entryMultiple generics now supply both the diabetes and weight-loss indications.

What this entry does not yet cover

What follows is unfinished work on our side, not a finding about Liraglutide.

Nothing outstanding on this one.

Sources

The studies that matter

  • SCALE Obesity2010s

    Adults on the weight-loss dose lost an average of about 8% of body weight over 56 weeks, the basis for the Saxenda approval.

  • LEADER cardiovascular trial2016

    In 9,340 patients with type 2 diabetes and high cardiovascular risk, liraglutide cut major cardiac events by 13%, the first GLP-1 to prove cardiovascular benefit.

  • STEP 8 head-to-head2022

    Directly compared with semaglutide, liraglutide produced 6.4% weight loss versus semaglutide’s 15.8%, quantifying the efficacy gap.

  • Adolescent obesity trial2020

    A dedicated trial showed liraglutide significantly reduced body-mass measures in adolescents, supporting the first pediatric GLP-1 weight-management approval.

  • Diabetes glycemic trials2000s-2010s

    Multiple trials established strong blood-sugar control in type 2 diabetes.